Mark Cuban’s online pharmacy venture will have an impact, but initially it won’t be as disruptive to the prescription drug market as some project. The company’s impact on the market will be limited by the number and type (generic) of drugs offered, as …
Many were hoping Delta would be the last in a chain of variants of increasing transmission and virulence. Not one but two new forms of Omicron, BA.1 and BA.2, have put a swift end to that hope.
Researchers at the University of Illinois Chicago have developed a “decoy” protein that tricks SARS-CoV-2 into binding to it instead of to host cells.
Capital Rx is the nation’s fastest-growing PBM. Its business model has the potential to shake things up in an industry that could use more visibility in the ways in which prescription drugs are priced.
Despite the decision to restrict coverage of Aduhelm, the Centers for Medicare and Medicaid Services (CMS) is not taking over FDA’s job as arbiter of which drugs ought to be licensed. It is simply doing a different job.
Researchers at the University of Hong Kong are exploring a novel vaccine strategy aimed at increasing antibody activity throughout the respiratory system and supporting long-term protection against infection. This approach consists of a two-step proces…
During the first six months of the pandemic, almost a quarter of nurses reported being depressed and over half had anxiety, according to a new study.
New studies show that cannabinoids may help to slow the spread of Covid-19 and its variants.
The newest paper from the University of Washington by McCallum et al. is a tour de force in helping us understand the properties of Omicron in molecular detail.
A new study sheds light on one of the roles SARS-CoV-2 NSP13 (nonstructural protein 13) plays in the virus’ initial attack on the immune system, which is to degrade a kinase enzyme upstream of interferon, TBK1 (TANK-binding kinase 1).
